arGEN-X B.V., Lonza, Kyowa Hakko Kirin deal

arGEN-X received non-exclusive rights from Lonza and Kyowa's BioWa Inc. subsidiary to apply the Potelligent CHOK1SV cell line technology to arGEN-X's ARGX-110. The human mAb against CD70 (CD27L) is in Phase Ib testing for CD70-positive cancer. The Potelligent CHOK1SV cell line increases antibody-dependent cellular cytotoxicity (ADCC). The parties declined to disclose financial terms. ...